-
Your selected country is
Sweden
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
BD Oncomark™ Anti-Human CD79b FITC/Kappa PE/CD19 PerCP-Cy™5.5
(RUO (GMP))Anti-Human CD79b FITC/Kappa PE/CD19 PerCP-Cy™5.5
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Description
CD79b, clone SN8 (3A2-2E7-1F5), is generated from the fusion of NS-1 myeloma cells with spleen cells from BALB/c mice immunized with an antigen prepared from the membrane of B-prolymphocytic leukemia (B-PLL) cells. Anti-Kappa, clone TB28-2, is derived from hybridization of mouse P3-X63-Ag8.653 myeloma cells with cells from CB6 (BC57b x BALB/c) mice immunized with human IgG-κ myeloma protein. CD19, clone SJ25C1, is derived from the hybridization of mouse Sp2/0 cells with spleen cells from BALB/c mice immunized with NALM1 + NALM16 cells. CD79b, clone SN8, reacts with the CD79b protein and the epitope lies on the extra domain of the peptide. CD79b is helpful in delineating signal transduction pathway activated via antibody receptors during different stages of B-cell differentiation. Anti-Kappa is specific for kappa light chains of human immunoglobulins. CD19 (SJ25C1) recognizes a 90-kilodalton (kd) antigen that is present on human B lymphocytes.
Preparation And Storage
Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.
Description | Clone | Isotype | EntrezGene ID |
---|---|---|---|
CD79B FITC | 3A2-2E7 | IgG1, κ | 974 |
CD19 PerCP-Cy5.5 | SJ25C1 | IgG1, κ | 930 |
Ig, κ light chain PE | TB28-2 | IgG1, κ | 931 |
Development References (19)
-
Braylan RC, Benson NA, Iturraspe J. Analysis of lymphomas by flow cytometry: current and emerging strategies. Ann NY Acad Sci. 1993; 677:364-378. (Biology).
-
Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in healthcare settings. MMWR. 1988; 37:377-388. (Biology).
-
Chung J, Gong G, Huh J, Khang SK, Ro JY. Flow cytometric immunophenotyping in fine-needle aspiration of lymph nodes. J Korean Med Sci. 1999; 14:393-400. (Biology).
-
Clinical and Laboratory Standards Institute. 2005. (Biology).
-
Davidson B, Risberg B, Berner A, Smeland EB, Torlakovic E. Evaluation of lymphoid cell populations in cytology specimens using flow cytometry and polymerase chain reaction. Diagn Mol Pathol. 1999; 8:183-188. (Biology).
-
Engel P, Wagner N, Tedder TF. Schlossman SF, Boumsell L, Gilks W, et al, ed. Leucocyte Typing V: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1995:667-679.
-
Geary WA, Frierson HF, Innes DJ, Normansell DE. Quantitative criteria for clonality in the diagnosis of B-cell non-Hodgkin's lymphoma by flow cytometry. Mod Pathol. 1993; 6:155-161. (Biology).
-
Johnson A, Cavallin-Stahl E, Akerman M. Flow cytometric light chain analysis of peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma. Br J Cancer. 1985; 52(2):159-168. (Biology). View Reference
-
Kubagawa H, Gathings WE, Levitt D, Kearney JF, Cooper MD. Immunoglobulin isotype expression of normal pre-B cells as determined by immunofluorescence.. J Clin Immunol. 1982; 2(4):264-9. (Biology). View Reference
-
Letwin BW, Wallace PK, Muirhead KA, Hensler GL, Kashatus WH, Horan PK. An improved clonal excess assay using flow cytometry and B-cell gating. Blood. 1990; 75:1178-1185. (Biology).
-
Loken MR, Shah VO, Dattilio K, Civin C. Flow cytometric analysis of human bone marrow, I: Normal erythroid development. Blood. 1987; 69:255-263. (Biology).
-
Moldenhauer G, Dörken B, Schwartz R, Pezzutto A, Knops J, Hammerling GJ. Analysis of ten B lymphocyte-specific workshop monoclonal antibodies. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, ed. Leukocyte Typing II: Human B Lymphocytes. New York: Springer-Verlag; 1986:61-67.
-
Nadler LM. B Cell/Leukemia Panel Workshop: summary and comments. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, ed. Leukocyte Typing II: Human B Lymphocytes. New York: Springer-Verlag; 1986:3-43.
-
Okazaki M, Luo Y, Han T, Yoshida M, Seon BK. Three new monoclonal antibodies that define a unique antigen associated with prolymphocytic leukemia/non-Hodgkin's lymphoma and are effectively internalized after binding to the cell surface antigen. Blood. 1993; 81(1):84-94. (Biology). View Reference
-
Reichert T, DeBruyere M, Deneys V, et al. Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopathol. 1991; 60(2):190-208. (Biology). View Reference
-
Sanchez M, Misulovin Z, Burkhardt AL, et al. Signal transduction by immunoglobulin is mediated through Ig α and Ig β. J Exp Med. 1993; 178:1049-1055. (Biology).
-
Tedder TF, Zhou LJ, Engel P. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol Today. 1994; 15(9):437-442. (Biology). View Reference
-
Zardawi IM, Jain S, Bennett G. Flow-cytometric algorithm on fine-needle aspirates for the clinical workup of patients with lymphadenopathy. Diagn Cytopathol. 1998; 19:274-278. (Biology).
-
Zomas AP, Matutes E, Morilla R, Owusu-Ankomah K, Seon BK, Catovsky D. Expression of the immunoglobulin-associated protein B29 in B cell disorders with the monoclonal antibody SN8 (CD79b). Leukemia. 1996; 10(12):1966-1970. (Biology). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Although not required, these products are manufactured in accordance with Good Manufacturing Practices.